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In this study the plasma level of zinc and Magnesium were determined in 50 type 
2 diabetic patients and 50 healthy people. The sampling of type 2 diabetic patients 
were randomized. Diabetic patients studied were without any complications. 
Samples were analyzed using Randox kit with Spectrophotometric method. The 
plasma zinc (116.78±5.51 µg dL _,) and Magnesium (1.55±0.12 meq L _,) levels 
significantly decreased in type 2 diabetic patients (p<0.001) when compared with 
control groups (146.86±9.06 µg dL-', 1.84±0.10 meq L-', respectively). It is 
concluded that type 2 diabetes mellitus can result in changes in Zinc and 
Magnesium levels. The decreased plasma Zn and Mg that we demonstrated in this 
study in patients with type 2 diabetes mellitus probably reduce insulin sensitivity 
and may increase risk of secondary complications, it maybe prudent in clinical 
practice to periodically monitor plasma Zn and Mg concentrations in type 2 
diabetic patients. If plasma Zn and Mg were decreased, an intervention to increase 
of dietary intake of Zn and Mg may be beneficial for these patients. 
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INTRODUCTION 
Diabetes mellitus 1s a heterogenous disease 
characterized by an absolute or relative deficiency of 
insulin as well as insulin resistance. Some trace elements 
like zinc and magnesium are important for human growth 
and body's biological functions. They most commonly 
function as coenzymes and cofactor for metabolic 
reactions and thus help support basic cellular reactions 
(i.e., glycolysis, the citric acid cycle, lipid and amino acid 
metabolism) required to maintain energy production and 
life (Shils et al., 1999). Tlie relationship between trace 
elements and carbohydrate metabolism have regained 
consideration interest over the last few years. The 
importance of the trace elements in living organisms was 
shown over a century ago. Lamb et al. (1958) 
demonsterated the existence of a number of a trace-metal­
containing enzymes (metalloenzymes) of importance to 
the structural and functional integrity of the living cells. 
Growing concern with enviromental factors in human 
health over the last few years has aroused renewed 
interest in trace elements (Lamb et al., 1958). 
Magnesium is an important element for health and 
disease. Magnesium, the second most abundant 
intracellular cation, has been identified as a cofactor in 
over 300 enzymatic reactions, involving energy 
metabolism and protein and nucleic acid synthesis 
(de Walk, 1999). Magnesium may participate in the 
pathogenesis of diabetes complications and may 
contribute to the increased risk of sudden death 
associated with diabetes (Franz and Bantle, 1999). 
The function of zinc in the body metabolism is based 
on its enzymatic affinity, way of a zinc enzyme complex or 
zinc metalloenzyme. In humans and animals, diabetes 
maybe results in disturbance of this vital trace elements 
(Kinlaw et al., 1983). In most mammals, insulin is stored 
as zinc crystals and is likely secreted in zinc form zinc 
has important role in modulating the immune system and 
its dysfunction in diabetes mellitus may be related in 
part to the status of zinc (Mocchegianai eta/., 1989). Lack 
or inadequate supply of such nutrients produces a 
functional impairment or can results in disease. The 
clinical significance and evaluation of zinc and 
Magnesium in regard to different diseases including 
diabetes mellitus remain conflicting as well as 
controversial and many questions still remain 
unanswered. Numerous authors have evaluated trace 
element levels and status in diabetic subjects yet, often 
inconsistent and contradictory results have been resulted 
(Walter et al., 1991; Zargar et al., 1998;El-Yazigiet 
al., 1991 ). The concept behind this study is to determine 
the plasma levels of zinc and magnesium in 
Table 1: Characteristic of the diabetic patients and control groups 
Characteristic Diabtic patients Control groups 
No. ofsubjects 50 50 
Age fyears) 48.47±6.87 47.66±5.68 
Sex Male= 20 Male= 22 
Female= 30 Female= 28 
Duration of diabetes fyears) 2.78±0.74 
Fast blood sugar (mg dL- 1) 204.54±32.42 85.62±8.31 
Glycated haemoglobin (%2 10.67±1.06 6.31±0.83 
type 2 diabetic patients and compared with control 
groups in diabetes center of Golestan University of 
Medical Sciences. 
MATERIALS AND METHODS 
The sampling of type 2 diabetic patients were 
randomized which carried out on 50 type 2 diabetic 
patients. Patients were chosen from the patients referred 
to the Department ofDiabetes Center in 5th Azar hospital 
in Gorgan University of Medical Sciences (2005) and also 
50 healthy people for comparing of patients with them 
were chosen. Diabetic patients studied had no evidence 
of vascular complications including hypertension, 
coronary artery disease and etc., Healthy people was 
defined as an absence of major medical illness, no 
hospital admissions, no current medication and a 
subjective perception of good health as determined by 
health questionnaire. Neither of diabetic patients and 
healthy people received any medication during this study. 
Characteristics of diabetic patients and control groups are 
shoV\Tll in the Table 1. Blood samples were obtained after 
an overnight fasting from the diabetic patients and 
control groups, in a heparinized tubes. Plasma is 
separated as soon as blood was taken. The plasma Fast 
Blood Sugar (FBS) and glycated haemoglobin (HbAl c) 
were determined for diabetic patients and control groups, 
using laboratory kits and spectrophotometry technique 
(model JENWAY 6105 UV/VIS) and plasma zinc (Zn) 
and Magnesium (Mg) were analyzed Randox kit (Hamster 
and Zak, 1985; Young, 1990) with Spectrophotometry 
method in the Laboratory of Biochemistry (Faculty of 
Medicine). Plasma FBS and HbAl c were determined with 
(Bammham and Trinder, 1972) and (Boer et al., 1992) 
methods, respectively. The findings were given to 
software SPSS-10 and analyzed by student' !-test 
analytical method. p<0.05 was significant. 
RESULTS AND DISCUSSION 
In the present study we determined the plasma levels 
of Zinc and Magnesium in 50 type 2 diabetes mellitus 
patients (20 men and 30 women) and 50 control groups (22 
men and 28 women). Table 2 shows that plasma levels of 
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Table 2: Plasma zinc and magnesium concenterations of type 2 diabetic 
patients and control groups 
Diabetic patients Control groups p-value 
n=50 n=50 
Zinc (µg dL-1) 116.78±5.51 146.86±9.06 <0.001 
Magnesium (meq L-1) 1.55±0.12 1.84±0.10 <0.001 
Zn an Mg were significantly decreased in type 2 diabetes 
mellitus when compared with control groups (p<0.001). 
There are varying reports on changes in plasma zinc 
and Mg in type 2 diabetic patients. Some of the studies 
showed no significant differences while some other 
showed a decrease. There are a few reports describing 
difference in plasma Zn and Mg between type 2 diabetic 
patients and healthy control. 
Patients with type 2 diabetes mellitus have an 
increased mortality and morbidity compared with control 
groups and are more likely to coroner artery disease, 
cerebrovascular and peripheral vascular disease 
(Karmel and McGee, 1979). The results of some studies 
showed that plasma Zn and Mg in type 2 diabetes 
mellitus patients were decreased (Walter et al., 1991; 
Walti et al., 2003; Evliaoglu et al., 2002) and no 
significant differences (Walter et al., 1991; Zargar et al., 
1998; Evliaoglu et al., 2002) when compared to control 
groups. The results of this study are in agreement with 
the results of some studies that plasma Zn and Mg levels 
in type 2 diabetic patients were significantly decreased 
(Walter et al., 1991; Walti et al., 2003; Evliaoglu et al., 
2002) when compared with control groups. But the results 
of this study are not in agreement with the findings of 
other studies (Walter et al., 1991; Zargar et al., 1998). 
Possible explanation for this situation is that there is loss 
of a large amollllt of Zn from the body via urine. The 
source of the Zn that is excreted remains incompletely 
resolved. There is a concurrent hypozincemia and a 
decrease in tissue Zn stores, but it is not clear if this is a 
results of the hyperzincuria or an independent event 
related to the effect of insulin or hypergcemia on loss of 
Zn from the tissue stores with a resultant loss of Zn to the 
plasma from where it is excreted with a net loss of total 
body Zn and eventual hypozincemia. 
The reasons why Mg decreasing occurs in diabetes 
are not clear but may include higher urinary losses or 
impaired absorption of Mg compared with healthy 
persons (Walti et al., 2003). Several studies reported 
increased urinary Mg excretion in type 1 and type 2 
diabetes (Sjogren et al., 1988; McNair et al., 1982; 
Fujii et al., 1982; Johnnsonet al., 1982; Brown et al., 1999; 
Roffi et al., 1994), whereas other studies folllld no 
significant differences in Mg excretion between diabetic 
patients and healthy control groups (Sjogren et al., 1986; 
El-Yazigi et al., 1993). Increased urinary 1.1g excretion due 
to hyperglycemia and osmotic diuresis may contribute to 
hypomagnesaemia in diabetes (McN air et al., 1982; 
Fujii et al., 1982; Johnnson et al., 1982). Several 
authors have suggested that impaired intestinal 
absorption might contribute to the low Mg status in 
diabetic patients (Dulach and Rayssiguier, 1983; 
Sheehan, 1991; Tosiello, 1996). The decreased plasma 
Zn and Mg that we demonsterated in this study in 
patients with type 2 diabetes mellitus probably reduce 
insulin sensitivity and may increase risk of secondary 
complications, it maybe prudent in clinical practice to 
periodically monitor plasma Zn and Mg concenterations 
in type 2 diabetic patients. If plasma Zn and Mg were 
decreased, an intervantion to increase of dietery intake of 
Zn and Mg may be bnefical for these patients. 
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